CFDA: Draft guidance? [RSABE / ABEL]

posted by libaiyi – China, 2018-06-13 05:39 (2231 d 23:07 ago) – Posting: # 18895
Views: 6,493

Thanks for you reply.

Another question,
how to write the null hypothesis and alternative hypothesis for BE based on FDA or EMA method?

Complete thread:

UA Flag
Activity
 Admin contact
23,113 posts in 4,858 threads, 1,644 registered users;
36 visitors (0 registered, 36 guests [including 9 identified bots]).
Forum time: 04:47 CEST (Europe/Vienna)

You can’t really say “similar” if it’s the same again you want.
“Similar” means something different.    Anthony Burgess

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5